Leadership Change

National Real Estate Advisors Names Kevin Verdi CEO, Succeeding Founder Kanne

Washington – September 15, 2026 -- National Real Estate Advisors will replace founder and CEO Jeffrey Kanne with Kevin Verdi, its Executive Vice President and Chief Investment Officer, effective January 2027, the institutional investment manager announced.

Kanne exits after more than 25 years building the firm into an institutional real estate platform

Kanne, who founded National in 2000, will retire from the CEO role after more than a quarter-century at the helm, during which the firm grew into an investment manager serving U.S. and international institutional investors. He will remain with National as a Special Advisor following the leadership change.

Donate Life America Names Madison Walter-Garcia as Next President & CEO

Richmond, Va. – September 15, 2026 -- Donate Life America (DLA) has named Madison Walter-Garcia, MPH, CHES, as its next President & CEO, effective September 21, succeeding David Fleming after more than 30 years of leadership.

Walter-Garcia Brings Nearly a Decade of CDC Partnership Experience to DLA

Walter-Garcia spent nearly ten years at the Centers for Disease Control and Prevention (CDC), most recently as Associate Director for Partnerships in the Division of Foodborne, Waterborne, and Environmental Diseases. She built partnership programs from the ground up, cultivated relationships with more than 1,000 stakeholders, and led a gift portfolio through the CDC Foundation exceeding $30 million.

ImmunoGenesis Adds Biopharma, Ex-USGA Chief to Board Ahead of 2027 Data

Houston – September 15, 2026 -- ImmunoGenesis has appointed Reza Mazhari, Ph.D., and Mike Davis to its Board of Directors as the clinical-stage biotech advances its lead immunotherapy candidate toward key data readouts in mid-2027.

ImmunoGenesis has initiated a Phase 1b trial for lead asset IMGS-001

IMGS-001, a cytotoxic checkpoint inhibitor targeting PD-L1 and PD-L2, is being studied for immune-excluded tumors, a category that accounts for more than half of all cancers. James Barlow, President and CEO of ImmunoGenesis, said the new board members will help shape pipeline, partnering and fundraising strategy for the company's next growth phase.

Algorand Names William Herkelrath CEO, Refocuses on Quantum Security

Dover, Del. – September 15, 2026 -- Algorand Foundation U.S. Inc. has appointed William Herkelrath as Chief Executive Officer, replacing Staci Warden after nearly five years at the helm of the public blockchain network.

Herkelrath takes over as Algorand pushes institutional and post-quantum strategy

Herkelrath officially assumed the CEO role on August 31, bringing two decades of experience across AI, enterprise software, institutional finance, and blockchain infrastructure. He previously co-founded K3 Labs, an AI-first automation platform for agent-managed workflows, and held leadership positions at Chainlink and Curv.

Icentia Names Ex-AliveCor Executive Sanjay Voleti as New CEO

Quebec City – September 15, 2026 -- Icentia has appointed Sanjay Voleti as President and CEO, tasking the digital health veteran with accelerating the cardiac diagnostics company's commercial expansion in the United States.

Voleti succeeds co-founder Pierre Paquet after the company built operations across four countries

Voleti replaces co-founder Pierre Paquet, who led Icentia from its founding as a Canadian health-tech startup into an international operator with a presence in Canada, the United Kingdom, Ireland and the United States. Paquet said the company's CardioSTAT platform has become a reference point in continuous ambulatory ECG recording and that the time had come to bring in a leader experienced in scaling technology companies internationally.